NYSE:KVUE

Kenvue stock price slips as Kimberly-Clark drops, deal vote stays in focus

Kenvue Inc shares dropped roughly 1.7% to $17.29 Wednesday afternoon, despite a slight uptick in the broader market. Kimberly-Clark, the Kleenex maker set to acquire Kenvue, slipped around 1.8%. The consumer staples sector also remained under pressure.

21 January 2026

NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue stock steadies as Kimberly-Clark deal vote nears, with lawsuits in the mix

Kenvue Inc shares edged down roughly 0.1% to $17.58 in early Wednesday trading, while Kimberly-Clark, the potential buyer, held steady at $101.44.

21 January 2026

NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue stock ticks up as investors size up Kimberly-Clark takeover vote in days

Kenvue shares ticked up 0.6% to $17.31 in late-morning trading Tuesday in New York, a modest gain as investors held back ahead of a late-January vote on the potential sale of the Tylenol and Band-Aid maker to Kimberly-Clark.

20 January 2026

NYSE:KMB·NYSE:KVUE·Stock Market

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson shares slipped 0.4% to $218.66 on Friday, the last session before U.S. markets shut for the Martin Luther King Jr. Day holiday.

18 January 2026

Earnings Reports·NYSE:ABT·NYSE:JNJ·NYSE:KMB·NYSE:KVUE·NYSE:MRK·NYSE:PFE·Stock Market

Kenvue stock has a new catalyst: ISS backs Kimberly-Clark merger ahead of Jan. 29 vote

Kenvue shares slipped 0.35% to close at $17.20 on Friday, as investors digested a crucial nod for its planned sale to Kimberly-Clark. Proxy adviser Institutional Shareholder Services gave the green light, saying “on balance, support for the transaction is warranted.” Still, ISS flagged ongoing market jitters and legal risks as key concerns for shareholders. With proxy advisers often influencing big institutional votes, both companies’ investors are set to weigh in on Jan. 29.

18 January 2026

NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue stock: ISS backs Kimberly-Clark deal as lawsuit filings add pressure ahead of vote

Kenvue Inc shares ended slightly lower on Friday after proxy adviser ISS backed Kimberly-Clark’s takeover proposal, keeping attention on a shareholder vote later this month.

17 January 2026

NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue stock is up today — here’s what the Kimberly-Clark deal is worth now

Kenvue Inc shares rose about 0.5% to $17.21 on Thursday, as Kimberly-Clark — the would-be buyer — gained roughly 0.7% to $99.81, lifting the implied value of the takeover offer. The broader market was firmer, with the S&P 500’s main ETF up about 0.6%, while the consumer staples ETF was little changed.

15 January 2026

NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue Inc shares ticked up roughly 0.4% to $17.08 on Wednesday, continuing a stretch of modest fluctuations as the stock moves mainly on deal speculation. The gain followed Kimberly-Clark’s submission of extra documents to the U.S. Securities and Exchange Commission related to its intended purchase of the consumer health firm.

14 January 2026

Mergers and Acquisitions·NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue stock (KVUE) ends week lower as Jan. 29 Kimberly-Clark deal vote nears

Kenvue Inc shares slipped on Friday, closing down about 1% at $16.83, as traders headed into the weekend still pricing in a gap to Kimberly-Clark’s takeover terms. Kimberly-Clark shares ended down about 1% at $97.92.

12 January 2026

NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy

Kenvue Inc shares slipped 0.9% on Friday, ending at $16.83 after trading between $16.75 and $17.05, retracing some of Thursday’s gains. The Options Clearing Corporation highlighted a shareholder vote set for Jan. 29 on Kenvue’s proposed merger with Kimberly-Clark and detailed a planned adjustment to KVUE options once the deal closes. They warned terms might shift as new details emerge.

10 January 2026

NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue stock: Options memo spotlights Jan. 29 vote on Kimberly-Clark deal

The Options Clearing Corporation on Friday announced a planned adjustment for Kenvue Inc. options before the Jan. 29 shareholder vote on the company’s proposed merger with Kimberly-Clark. Kenvue shares last changed hands at $16.83, slipping roughly 1% after U.S. markets closed.

10 January 2026

NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

Kenvue Inc shares rose 0.8% to $16.87 in mid-morning trade on Thursday after shareholder law firm Kahn Swick & Foti said it was investigating the consumer health group’s pending sale to Kimberly-Clark. The firm said it is reviewing whether Kenvue’s board ran a fair process and secured the best price for shareholders. PR Newswire

8 January 2026

NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue Stock (NYSE: KVUE) News Today: Kimberly-Clark Deal Update, Insider Buying, Analyst Forecasts — December 25, 2025

U.S. markets are closed for Christmas Day, but investors aren’t exactly “off the clock” when it comes to Kenvue Inc.. The former Johnson & Johnson consumer-health spinout has become a live merger-arbitrage story after Kimberly-Clark agreed to buy it, and KVUE’s price action is now a referendum on deal timing, legal risk, and whether the takeover terms hold up through 2026.

25 December 2025

Insider Activity·NYSE:KMB·NYSE:KVUE

Johnson & Johnson Stock After Hours Dec. 23, 2025: JNJ Slides on Record Talc Verdict — What to Know Before Wednesday’s Open

Johnson & Johnson ended Tuesday’s session lower and traded narrowly after the closing bell as investors digested a fresh—and record-size—legal headline tied to the company’s long-running talc litigation. With U.S. markets heading into a holiday-shortened session on Wednesday, December 24, the near-term setup is as much about liquidity and headline risk as it is about fundamentals.

24 December 2025

NYSE:JNJ·NYSE:KVUE

Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Inc. is trading in a very particular kind of gravity field on December 23, 2025: part consumer-health staple, part legal-headline lightning rod, and—most importantly right now—part merger-arbitrage instrument because of its pending acquisition by Kimberly-Clark.

23 December 2025

NYSE:JNJ·NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue Inc. — the consumer-health company behind Tylenol, Band-Aid, Listerine, Aveeno, and Neutrogena — is trading in a very particular kind of market right now: not just “up or down,” but “how likely is the Kimberly-Clark deal to close, and what’s the risk premium?”

19 December 2025

Financial Forecasts·NYSE:KMB·NYSE:KVUE

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Inc.—the consumer health company behind brands such as Tylenol, Band-Aid, Listerine, Neutrogena, and Aveeno—is trading in a market that feels less like “buy-and-hold fundamentals” and more like “event-driven probability.” The reason: Kimberly-Clark’s planned acquisition of Kenvue, a deal that has put a very visible “price anchor” on KVUE… while lawsuits, regulatory steps, and the calendar to closing keep the stock from simply snapping to the offer value. investors.kenvue.com+2Reuters+2

15 December 2025

NYSE:KMB·NYSE:KVUE·Stock Market

Kenvue (KVUE) Stock Today: Dividend Payout, Insider Buying and Kimberly-Clark Deal in Focus – November 26, 2025

Kenvue Inc. — the Johnson & Johnson consumer-health spin‑off behind Tylenol, Listerine and Neutrogena — is back in the spotlight on Wednesday, November 26, 2025, as the stock trades higher on dividend payday, fresh insider and hedge‑fund buying disclosures, and ongoing scrutiny of its $48.7 billion sale to Kimberly‑Clark. Wikipedia+1

26 November 2025

Dividends·NYSE:KVUE·Stock Market

KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

Kenvue Inc. — the consumer health company behind Tylenol, Band‑Aid, Neutrogena and Listerine — is back in focus this weekend after another strong session on Friday.

22 November 2025

NYSE:KMB·NYSE:KVUE

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

KVUE softened today after Monday’s developments in federal litigation tied to claims that prenatal acetaminophen use raises autism risk. A three‑judge appeals panel questioned the lower court’s dismissal of those cases, opening the door to their potential return and keeping headline risk front‑and‑center for the stock. Reuters

18 November 2025

Dividends·Mergers & Acquisitions·NYSE:KMB·NYSE:KVUE·Pharmaceuticals·Stock Market

NYSE:KVUE 18 November 2025 - 21 January 2026